Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma.

Abstract

PURPOSE:

The aim of this study was to determine the pharmacokinetics of low-dose nedaplatin combined with paclitaxel and radiation therapy in patients having non-small-cell lung carcinoma and establish the optimal dosage regimen for low-dose nedaplatin. We also evaluated predictive accuracy of reported formulas to estimate the area under the plasma concentration-time curve (AUC) of low-dose nedaplatin.

PATIENTS AND METHODS:

A total of 19 patients were administered a constant intravenous infusion of 20 mg/m(2) body surface area (BSA) nedaplatin for an hour, and blood samples were collected at 1, 2, 3, 4, 6, 8, and 19 h after the administration. Plasma concentrations of unbound platinum were measured, and the actual value of platinum AUC (actual AUC) was calculated based on these data. The predicted value of platinum AUC (predicted AUC) was determined by three predictive methods reported in previous studies, consisting of Bayesian method, limited sampling strategies with plasma concentration at a single time point, and simple formula method (SFM) without measured plasma concentration. Three error indices, mean prediction error (ME, measure of bias), mean absolute error (MAE, measure of accuracy), and root mean squared prediction error (RMSE, measure of precision), were obtained from the difference between the actual and the predicted AUC, to compare the accuracy between the three predictive methods.

RESULTS:

The AUC showed more than threefold inter-patient variation, and there was a favorable correlation between nedaplatin clearance and creatinine clearance (Ccr) (r = 0.832, P < 0.01). In three error indices, MAE and RMSE showed significant difference between the three AUC predictive methods, and the method of SFM had the most favorable results, in which %ME, %MAE, and %RMSE were 5.5, 10.7, and 15.4, respectively.

CONCLUSIONS:

The dosage regimen of low-dose nedaplatin should be established based on Ccr rather than on BSA. Since prediction accuracy of SFM, which did not require measured plasma concentration, was most favorable among the three methods evaluated in this study, SFM could be the most practical method to predict AUC of low-dose nedaplatin in a clinical situation judging from its high accuracy in predicting AUC without measured plasma concentration.

• Authors: Takenori Niioka, Tsukasa Uno, Norio Yasui-Furukori, Takenori Takahata, Mikiko Shimizu, Kazunobu Sugawara, Tomonori Tateishi
• Journal: Cancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 59 Issue 5 Pg. 575-80 (Apr 2007) ISSN: 0344-5704 [Print] Germany
• PMID: 16912889 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Antineoplastic Agents
• Organoplatinum Compounds
• nedaplatin

Topics

• Aged
• Algorithms
• Antineoplastic Agents (administration & dosage, pharmacokinetics, therapeutic use)
• Area Under Curve
• Body Surface Area
• Carcinoma, Non-Small-Cell Lung (drug therapy, metabolism)
• Data Interpretation, Statistical
• Female
• Half-Life
• Humans
• Infusions, Intravenous
• Lung Neoplasms (drug therapy, metabolism)
• Male
• Middle Aged
• Organoplatinum Compounds (administration & dosage, pharmacokinetics, therapeutic use)
• Predictive Value of Tests
• Reproducibility of Results